to reduce PTH despite inhibition of its metabolism suggests a direct action of this 'prodrug' on the parathyroid gland, but the mechanism underlying this activity is not yet known.
Introduction
Vitamin D therapy is widely used for the treatment of the secondary hyperparathyroidism associated with chronic renal failure [1, 2] . The active hormonal form of vitamin D, 1,25-dihydroxyvitamin D, and its analogues can reduce serum PTH levels by repressing PTH gene transcription [3, 4] and blocking parathyroid gland proliferation [5] . These actions are mediated by the vitamin D receptor (VDR) present in the PTHsecreting chief cells of the parathyroid glands [6] [7] [8] . High-affinity binding to the VDR generally requires hydroxyl groups at carbon 1 and at carbon 25 (or nearby carbons of the side chain). The synthetic prohormones, 1a(OH)D 3 (alfacalcidol) and 1a(OH)D 2 (doxercalciferol) (Figure 1 ), are widely used for treatment of secondary hyperparathyroidism of kidney disease, but these compounds have relatively low intrinsic affinity for the VDR compared to active compounds such as calcitriol [9] , and have been thought to require systemic activation to exert their effects on the parathyroid glands.
An unpublished study by Olgaard and coworkers demonstrated a direct suppression of PTH secretion by 1a(OH)D 3 in parathyroid tissue culture [10] . This initial study did not investigate whether suppression of PTH by 1a(OH)D 3 required conversion to a more active metabolite. We have shown that parathyroid cells possess vitamin D hydroxylase (CYP24) activity [11, 12] , and may therefore be capable of activating vitamin D prodrugs such as 1a(OH)D 3 in situ. A recent report by Correa et al. [13] confirmed the existence of CYP24 expression in human parathyroid tissue as well as the presence of mRNAs for both 25-hydroxyvitamin D 1a-hydroxylase (CYP27B1) and vitamin D 25-hydroxylase (CYP27A1). Although hydroxylase enzyme activity was not demonstrated, these findings suggest the possibility that the PTH suppressive activity of 1a(OH)D 3 and 1a(OH)D 2 may be due, at least in part, to conversion to active metabolites in parathyroid cells.
In the present study, we have examined the in vitro suppression of PTH secretion by several vitamin D prodrugs lacking side chain hydroxyl groups. [ 3 H]-1a (OH)D 2 was used to follow the metabolism and potential activation of 1a-hydroxyvitamin D compounds by parathyroid cells. The effect of blocking metabolism with the cytochrome P450 inhibitor ketoconazole on the ability of the 1a(OH)D 2 to suppress PTH was assessed. Demonstration of direct effects on the parathyroid glands of vitamin D prodrugs could have important implications for the design of vitamin D analogues for the treatment of secondary hyperparathyroidism.
Methods

Preparation of dispersed bovine parathyroid cells
Dispersed bovine parathyroid cells were prepared as previously described [14] . Briefly, bovine parathyroid glands (obtained from MBH Enterprises, Tampa, FL, USA) were trimmed of extraneous fatty tissue, sliced to 0.5 mm thickness with a tissue slicer (Stadie Riggs; Thomas Scientific, Swedesboro, NJ) and placed in a mixture of DME:Ham's F-12 medium (50:50) containing 0.5 mM calcium and collagenase (3000 U/ml of collagenase XI-S; Sigma, St Louis, MO, USA). The suspension (10 ml media per gram of tissue) was agitated in a shaking water bath at 37 C for 90 min. Periodic passage of the mixture through the tip of a 10 ml pippette assisted in the disaggregation. The digested tissue was washed three times with serum-free culture medium containing DME:Ham's F-12 (50:50), 1 mM CaCl 2 , 15 mM Hepes, 100 IU/ml penicillin, 100 mg/ml streptomycin, 5 mg/ml insulin, 5 mg/ml holo-transferrin, 2 mM glutamine, 1% non-essential amino acids and 0.1% bovine serum albumin (fraction V).
Dispersed cells were plated in 12-well culture plates at 0.2 Â 10 6 /well in the above medium containing 4% newborn calf serum. After 24 h, the medium was replaced with serumfree medium. The medium was changed every 2-3 days of culture.
Assessment of PTH suppression activity
Primary cultures of bovine parathyroid cells were grown to confluency in serum-free medium as previously described [15] , and then treated for 72 h with 0.1, 1.0, 10 and 100 nM 1,25(OH) 2 D 3 , 1a(OH)D 3 , 1a(OH)D 2 or BCI-210 with daily changes of medium. The cells were then changed into fresh medium and the amount of PTH secreted during a 4 h incubation was determined using an ELISA kit (Immutopics, San Capistrano, CA).
To determine the effects of ketoconazole, an inhibitor of metabolism, on PTH, confluent monolayers were treated with 1a(OH)D 2 (100 nM) for 48 h with media changes every 12 h. RNA was harvested from the cells using RNAzol B (Cinna/Biotecx), resolved on 1.2% agarose/formaldehyde gels and transferred to nylon membrane (Zeta-Probe, Bio-Rad). PTH mRNA and 18S rRNA were measured by hybridizing the membranes with riboprobes described previously [16] . The data are expressed as the ratio of PTH mRNA to 18S rRNA. Radioactivity in the aqueous phase of the extraction was measured to assess the amount of conversion to side chain-cleaved metabolites.
Metabolism
Results
Suppression of PTH in vitro
The ability of the 1a-hydroxy analogues to suppress PTH was assessed in vitro in cultures of bovine parathyroid cells. The structures of the analogues The high activity of BCI-210, which was designed to be resistant to both 24-and 25-hydroxylation, suggests that the 1a-hydroxy compounds either do not require activation or that this compound is activated by an alternative pathway such as 26-hydroxylation.
Metabolism of 1(OH)D 2 in bovine parathyroid cells
To determine if the 1a-hydroxy compounds may be converted to more active metabolites, parathyroid cells were incubated with To confirm the identities of these metabolites, the putative 1,24(OH) 2 D 2 and 1,25(OH) 2 D 2 peaks were isolated and rechromatographed on reverse phase HPLC (data not shown). The radioactive peaks co-eluted with the internal standards, consistent with their identities as 1,24(OH) 2 D 2 and 1,25(OH) 2 D 2 . A third metabolite peak in the normal phase HPLC profile was observed at fraction 38, in the position expected for 1,26(OH) 2 D 2 , but the lack of a standard prevented its further analysis. There was also a progressive increase in radioactivity in the methanol strip, indicating the presence of even more polar metabolites.
The amount of the metabolites present represented a very small proportion of the intitial [ 3 H]1a(OH)D 2 as illustrated in Figure 3B , in which the scale of the y-axis of Figure 3A is levels were highest. In addition, we found these dihydroxylated metabolites predominantly in the medium rather than the cells (data not shown).
Effect of ketoconazole on 1a(OH)D 2 metabolism and PTH suppression
The necessity of side chain hydroxylation in the suppression of PTH by 1a(OH)D 2 was examined using the competitive cytochrome P450 inhibitor Figure 4 , the rate of 1a(OH)D 2 metabolism in the absence of ketoconazole increased with each time period, presumably owing to the progressive induction of the 24-hydroxylase. Metabolism was completely blocked by the presence of ketoconazole; water-soluble radioactivity was the same as the no cell control at the end of each time period. Furthermore, HPLC analysis of cell and medium extracts demonstrated that no detectable dihydroxylated metabolites were produced in the presence of ketoconazole. Figure 5 shows representative HPLC profiles of combined cell plus medium extracts from cells at the end of the final incubation period. These findings clearly show that 1,24(OH) 2 D 2 and 1,25(OH) 2 D 2 were not produced when ketoconazole was replenished every 12 h.
We next examined the PTH mRNA levels in cells treated with 1a(OH)D 2 (or vehicle) with or without ketoconazole under conditions identical to those above. As shown in Figure 6 , 1a(OH)D 2 alone decreased PTH mRNA levels by 50% comparable to the reduction in PTH secretion shown in Figure 2 . Interestingly, ketoconazole alone also reduced PTH mRNA by an as yet unknown mechanism. In the presence of ketoconazole, 1a(OH)D 2 further suppressed PTH mRNA by about 55%, as effectively as in the absence of ketoconazole. Similar results were obtained in two additional experiments in different cell preparations treated in the same manner.
Discussion
The parathyroid glands were definitively identified as a vitamin D target tissue soon after characterization of the active form of vitamin D, 1,25(OH) 2 D 3 [6] [7] [8] . The glands contain a high content of VDR, and 1,25(OH) 2 D 3 has been shown to repress PTH gene transcription [3, 4] and inhibit parathyroid cell proliferation [5] through a VDR-dependent mechanism. The secondary hyperparathyroidism that develops in patients with chronic renal failure is believed to be attributable in part to the reduction of renal synthesis of 1,25(OH) 2 [18, 19] . Vitamin D prodrugs such as doxercalciferol owe their reduced calcaemic activity at least in part to the pharmacokinetics of their activation, which leads to sustained serum levels of active compound at more physiological concentrations than can be produced by administration of active compounds. Recent studies indicate that 1a(OH)D 3 produces a disproportionately large degree of PTH suppression relative to calcitriol, based on observed serum levels of active metabolites, suggesting either a direct suppressive effect of such prodrugs on the parathyroid, or activation in situ [20] .
To further clarify the structural requirements for effective vitamin D analogues in controlling parathyroid gland function, we investigated the ability of synthetic vitamin D prodrugs to directly suppress PTH synthesis and secretion. As reported by Nielsen et al., 1a(OH)D 3 was able to suppress PTH release from cultured bovine parathyroid cells. A similar suppression was observed in the present study with 1a(OH)D 2 and BCI-210. BCI-210 is a novel prodrug with a 24 (R) methyl group and a 25-27 double bond that is designed to resist both 24-and 25-hydroxylation ( Figure 1 ). All of these prodrugs produced less PTH suppression than an equivalent dose of 1,25(OH) 2 D 3 . Nonetheless, these findings clearly indicate that parathyroid cells can respond to vitamin D compounds lacking side chain hydroxyl groups, suggesting that systemic activation (i.e. 24-or 25-hydroxylation) of these compounds in vivo may not be necessary for suppression of PTH.
Vitamin D compounds such as 1a(OH)D 3 that lack a side chain hydroxyl group have relatively low affinity for the VDR (approximately 400-fold lower than calcitriol) [9] . One possibility, then, is that the activity of 1a(OH)D 3 [11, 15] . The amount of 1,24(OH) 2 D 2 produced was maximal at 8 h and then decreased. This could be attributed to the drop in 1a(OH)D 2 substrate concentration to lower levels at which 1,24(OH) 2 D 2 is not formed efficiently [14] and/or to further metabolism of 1,24(OH) 2 D 2 by CYP24 [11, 12] . The 24-hydroxylase can oxidize carbons 24 and 23 of the vitamin D side chain, leading to more polar metabolites with limited VDR affinity and PTH suppressing activity [11] , and eventually to side chain cleavage and inactivation [21] .
Production Figure 3B ). Furthermore, when ketoconazole was added to the cells every 12 h over a 48 h period, no 1,24(OH) 2 D 2 or 1,25(OH) 2 D 2 were detected at the end of the final 12 h treatment period. In addition, the aqueous counts, a measure of side chain cleavage via the C24 oxidation pathway, in the ketoconazoletreated samples were the same as those found with substrate incubated under identical conditions without cells for a 12 h period, indicating virtually no metabolism of the 1a(OH)D 2 . This complete block of metabolism did not prevent the reduction of PTH mRNA by 1a(OH)D 2 .
The ability of 1a(OH)D 2 , and probably the other vitamin D 'prodrugs', to suppress PTH without activation raises the question as to how this suppression is produced, given the relatively low VDR affinity of these compounds. One possibility is that these compounds accumulate in the parathyroid and reach intracellular concentrations sufficient to directly activate VDR and subsequently suppress PTH production. High intracellular levels of 1a(OH)D 2 were, in fact, observed in the metabolism studies, supporting this possibility. Intraparathyroid accumulation may also explain the clinical observation that, although patients who received equal doses of intravenous or oral 1a(OH)D 2 gave rise to equal serum levels of the active metabolite 1,25(OH) 2 D 2 , the dose of intravenous 1a(OH)D 2 required for equivalent PTH suppression was 40% of the oral dose [23] . This clinical data is consistent with the possibility that the initial high serum levels of 1a(OH)D 2 produced by intravenous administration deliver high levels of 1a(OH)D 2 to the parathyroid glands, enhancing the effectiveness [24] . VDR null mice did not develop parathyroid hyperplasia when fed a rescue diet containing 2.0% calcium, 1.25% phosphorus, 20% lactose and 2.2 U/g vitamin D 3 , whereas mice lacking both VDR and 1a-hydroxylase had enlarged parathyroid glands. The presence of a non-VDR receptor that is activated by high 1,25(OH) 2 D 3 was proposed. This as yet hypothetical receptor may mediate the effects of vitamin D compound lacking side chain hydroxyl groups including those investigated in the present study. One or both of these two alternate mechanisms may explain the high potency of (20S)-1a-hydroxy-2-methylene-19-nor-bishomopregnacalciferol (2M-bisP), an analogue lacking a side chain, to effectively lower PTH levels in both normal [25] and uraemic rats [26] .
The present study also revealed that ketoconazole itself can inhibit PTH, an observation that has not been previously reported. The addition of 1a(OH)D 2 produced a similar percentage reduction in PTH regardless of presence of ketoconazole, indicating both that the two compounds act via distinct mechanisms and that the mechanism utilized by 1a(OH)D 2 was not significantly impaired by ketoconazole. The mechanism for the suppression by ketoconazole is under investigation.
In summary, we have shown that PTH synthesis and secretion in cultured parathyroid cells is inhibited by exogenous vitamin D prodrugs lacking side chain hydroxyl groups. This suppression was not diminished when metabolism was blocked with the cytochrome P450 inhibitor ketoconazole indicating that side chain oxidation may not be required. This direct effect may be attributed to accumulation of 1a(OH)D 2 in the parathyroid to high intracellular levels that activate the vitamin D receptor or, possibly, to interaction with a novel receptor. Further studies are necessary to define the mechanism(s) involved. These findings may have important implications for the design of vitamin D analogues for treatment of secondary hyperparathyroidism.
